Published in Mol Cancer Res on April 01, 2004
Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med (2005) 3.60
Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest (2005) 1.58
Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech (2009) 1.53
A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo. PLoS One (2011) 1.48
SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal (2009) 1.41
Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg (2005) 1.38
The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem (2008) 1.27
SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer (2008) 1.23
Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol (2005) 1.22
Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis. Clin Exp Metastasis (2004) 1.22
CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol (2007) 1.16
Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol (2007) 1.14
Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp Biol Med (Maywood) (2008) 1.08
The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol (2012) 1.05
Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2. Mol Cell Biol (2007) 1.05
Loss of fibulin-5 binding to beta1 integrins inhibits tumor growth by increasing the level of ROS. Dis Model Mech (2010) 1.04
SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity. J Cell Biol (2011) 1.02
Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer (2010) 1.01
Human correlates of provocative questions in pancreatic pathology. Adv Anat Pathol (2012) 0.97
The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine. Br J Cancer (2010) 0.97
Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells. Cell Death Differ (2010) 0.97
Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br J Cancer (2007) 0.96
Differential Expression of SPARC in Intestinal-type Gastric Cancer Correlates with Tumor Progression and Nodal Spread. Transl Oncol (2009) 0.94
Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin Exp Metastasis (2007) 0.94
Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol (2014) 0.92
Activation state of stromal inflammatory cells in murine metastatic pancreatic adenocarcinoma. Am J Physiol Regul Integr Comp Physiol (2012) 0.92
Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival. J Exp Clin Cancer Res (2010) 0.90
Recruitment and retention: factors that affect pericyte migration. Cell Mol Life Sci (2013) 0.90
Secreted protein acidic and rich in cysteine (SPARC) in human skeletal muscle. J Histochem Cytochem (2008) 0.87
SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT. PLoS One (2012) 0.86
Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.85
Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma. Cancers (Basel) (2011) 0.84
SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression. Virchows Arch (2014) 0.82
Expression of Secreted Protein Acidic and Rich in Cysteine in the Stroma of a Colorectal Carcinoma is Associated With Patient Prognosis. Ann Coloproctol (2013) 0.82
Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice. Gut (2007) 0.82
Blockade of SOX4 mediated DNA repair by SPARC enhances radioresponse in medulloblastoma. Cancer Lett (2012) 0.82
Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer. Neoplasia (2011) 0.81
The expression of SPARC in human intracranial aneurysms and its relationship with MMP-2/-9. PLoS One (2013) 0.80
SIBLINGs and SPARC families: their emerging roles in pancreatic cancer. World J Gastroenterol (2014) 0.80
Genes related to suppression of malignant phenotype induced by Maitake D-Fraction in breast cancer cells. J Med Food (2013) 0.80
Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma. Onco Targets Ther (2015) 0.79
Expression analysis of SPARC/osteonectin in oral squamous cell carcinoma patients: from saliva to surgical specimen. Biomed Res Int (2013) 0.79
Loss of Sparc in p53-null Astrocytes Promotes Macrophage Activation and Phagocytosis Resulting in Decreased Tumor Size and Tumor Cell Survival. Brain Pathol (2015) 0.78
Looking to the future: biomarkers in the management of pancreatic adenocarcinoma. Int J Mol Sci (2011) 0.78
Novel role for matricellular proteins in the regulation of islet β cell survival: the effect of SPARC on survival, proliferation, and signaling. J Biol Chem (2014) 0.78
Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in mice. Cancer Biol Ther (2015) 0.77
Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1. Mol Cancer (2010) 0.76
Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Cancer Lett (2015) 0.76
Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication. World J Gastroenterol (2012) 0.76
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition. EMBO Mol Med (2016) 0.75
Datamining approach for automation of diagnosis of breast cancer in immunohistochemically stained tissue microarray images. Open Med Inform J (2010) 0.75
Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol (2002) 4.23
Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol (2009) 3.96
SPARC and tumor growth: where the seed meets the soil? J Cell Biochem (2004) 2.75
A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity. J Am Chem Soc (2008) 2.47
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene (2002) 2.41
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med (2009) 2.39
Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci U S A (2012) 2.24
Angiogenic role of LYVE-1-positive macrophages in adipose tissue. Circ Res (2007) 2.22
Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res (2007) 2.19
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res (2003) 2.08
Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest (2010) 1.90
SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem (2005) 1.70
SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem (2007) 1.68
Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest (2003) 1.67
Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proc Natl Acad Sci U S A (2011) 1.65
Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med (2008) 1.62
Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res (2008) 1.61
Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res (2008) 1.61
Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell (2013) 1.60
Lumbar intervertebral disc degeneration associated with axial and radiating low back pain in ageing SPARC-null mice. Pain (2012) 1.58
Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res (2005) 1.57
Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. J Immunol (2006) 1.53
Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech (2009) 1.53
Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One (2009) 1.53
A prototypic matricellular protein in the tumor microenvironment--where there's SPARC, there's fire. J Cell Biochem (2008) 1.50
Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res (2010) 1.48
Molecular pathway for cancer metastasis to bone. J Biol Chem (2003) 1.47
Fractal analysis of region-based vascular change in the normal and non-proliferative diabetic retina. Curr Eye Res (2002) 1.47
SPARC-null mice exhibit accelerated cutaneous wound closure. J Histochem Cytochem (2002) 1.47
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest (2013) 1.41
The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs (2011) 1.41
SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal (2009) 1.41
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther (2009) 1.40
27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep (2013) 1.39
A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun (2013) 1.37
Osteonectin-null mutation compromises osteoblast formation, maturation, and survival. Endocrinology (2003) 1.37
Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest (2006) 1.36
Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol (2003) 1.35
SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling. J Biol Chem (2008) 1.34
A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen (2006) 1.33
Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res (2007) 1.31
Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res (2004) 1.31
Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer (2006) 1.31
The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem (2008) 1.27
Compositional differences between infant and adult human corneal basement membranes. Invest Ophthalmol Vis Sci (2007) 1.25
RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov (2013) 1.25
SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem (2004) 1.24
Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg (2005) 1.23
BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther (2013) 1.19
Targeting vascular endothelium with avidin microbubbles. Ultrasound Med Biol (2005) 1.19
SPARC-null mice exhibit lower intraocular pressures. Invest Ophthalmol Vis Sci (2009) 1.18
Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer (2007) 1.18
Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice. J Cell Sci (2002) 1.17
Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia (2007) 1.17
IFATS collection: Combinatorial peptides identify alpha5beta1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells. Stem Cells (2008) 1.16
Revisiting the matricellular concept. Matrix Biol (2014) 1.14
Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int J Biochem Cell Biol (2004) 1.14
SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner. Cancer Res (2011) 1.13
r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction. PLoS One (2010) 1.13
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res (2007) 1.11
Fibulin-5, an integrin-binding matricellular protein: its function in development and disease. J Cell Commun Signal (2009) 1.11
Matricellular hevin regulates decorin production and collagen assembly. J Biol Chem (2006) 1.09
SPARC-like 1 regulates the terminal phase of radial glia-guided migration in the cerebral cortex. Neuron (2004) 1.09
Endothelial cell migration on surface-density gradients of fibronectin, VEGF, or both proteins. Langmuir (2007) 1.08
Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp Biol Med (Maywood) (2008) 1.08
Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J Cell Biochem (2002) 1.08
An in vitro model of posterior capsular opacity: SPARC and TGF-beta2 minimize epithelial-to-mesenchymal transition in lens epithelium. Invest Ophthalmol Vis Sci (2007) 1.08
Lack of "immunological fitness" during fasting in metabolically challenged animals. J Lipid Res (2012) 1.08
MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting. J Am Chem Soc (2010) 1.08
Targeted deletion of the SPARC gene accelerates disc degeneration in the aging mouse. J Histochem Cytochem (2005) 1.07
A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res (2007) 1.07
SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling. J Cell Biochem (2003) 1.07
SPARC is a VCAM-1 counter-ligand that mediates leukocyte transmigration. J Leukoc Biol (2006) 1.06
Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Clin Cancer Res (2011) 1.06
K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol Cancer Res (2009) 1.06
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther (2011) 1.06
Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium. PLoS One (2011) 1.06
TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression. Cancer Res (2012) 1.06
Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. Cancer Res (2008) 1.05
Biomaterial topography alters healing in vivo and monocyte/macrophage activation in vitro. J Biomed Mater Res A (2010) 1.05
Incorporation of bone marrow-derived Flk-1-expressing CD34+ cells in the endothelium of tumor vessels in the mouse brain. Neurosurgery (2006) 1.05
The matricellular protein SPARC is expressed in human trabecular meshwork. Exp Eye Res (2003) 1.04
Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. Am J Pathol (2003) 1.04
Loss of fibulin-5 binding to beta1 integrins inhibits tumor growth by increasing the level of ROS. Dis Model Mech (2010) 1.04
The effects of aging on tumor growth and angiogenesis are tumor-cell dependent. Int J Cancer (2007) 1.03
The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues. Bioorg Med Chem Lett (2008) 1.03
SPARC from olfactory ensheathing cells stimulates Schwann cells to promote neurite outgrowth and enhances spinal cord repair. J Neurosci (2007) 1.02
Expression and characterization of murine hevin (SC1), a member of the SPARC family of matricellular proteins. J Histochem Cytochem (2004) 1.02
SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity. J Cell Biol (2011) 1.02
HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion. Glia (2008) 1.01
The regulatory function of SPARC in vascular biology. Cell Mol Life Sci (2011) 1.01
PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol Cancer Ther (2013) 1.01
Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. Exp Biol Med (Maywood) (2010) 1.01
Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation (2009) 1.00
SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. Am J Physiol Heart Circ Physiol (2011) 1.00